Cargando…
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults
Adjuvant-containing subunit vaccines represent a promising approach for protection against tuberculosis (TB), but current candidates require refrigerated storage. Here we present results from a randomized, double-blinded Phase 1 clinical trial (NCT03722472) evaluating the safety, tolerability, and i...
Autores principales: | Sagawa, Zachary K., Goman, Cristina, Frevol, Aude, Blazevic, Azra, Tennant, Janice, Fisher, Bridget, Day, Tracey, Jackson, Stephen, Lemiale, Franck, Toussaint, Leon, Kalisz, Irene, Jiang, Joe, Ondrejcek, Lisa, Mohamath, Raodoh, Vergara, Julie, Lew, Alan, Beckmann, Anna Marie, Casper, Corey, Hoft, Daniel F., Fox, Christopher B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988862/ https://www.ncbi.nlm.nih.gov/pubmed/36878897 http://dx.doi.org/10.1038/s41467-023-36789-2 |
Ejemplares similares
-
The adjuvant GLA-AF enhances human intradermal vaccine
responses
por: Carter, Darrick, et al.
Publicado: (2018) -
Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine
por: Archer, Michelle C., et al.
Publicado: (2023) -
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018) -
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
por: Choi, Yu Hwa, et al.
Publicado: (2023) -
PO and ID BCG vaccination in humans induce distinct mucosal and
systemic immune responses and CD4+ T cell transcriptomal molecular
signatures
por: Hoft, DF, et al.
Publicado: (2017)